Blog Archive

Blog Archive

Thursday, April 14, 2011

postheadericon FDA must use caution with biosimilars

At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney cancer and related illnesses. 

Part of our role is to demystify for patients and their loved ones the array of treatment options available. Some of these treatment options include generic drugs. Some doctors regulatory prescribe, and we regularly take, generic drugs in place of the originals, because we know that the chemistry of these drugs is the same.

Read more...

0 ความคิดเห็น: